AzTrials
AzTrials

HealthyEarly Phase 1NCT06800183

Topical Tartrazine for Improved Skin Structure Visualization in Dermatology

A Early Phase 1 study testing Four-Chamber Tartrazine Patch across 3 Body Sites in people with Healthy and Dermoscopy, run by Johns Hopkins University at 1 site in United States.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to learn if the topical application of tartrazine, an FDA-approved food dye, can help improve the transparency of the skin in healthy volunteers. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Healthy, Dermoscopy, Optical Imaging
What is being tested?
Four-Chamber Tartrazine Patch across 3 Body Sites
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
1 siteUnited States
Study dates
11 May 2026to Dec 2026
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Healthy adults aged 18 and older
  • Willingness to comply with study procedures
  • Able to provide informed consent

Who cannot join

  • Known allergies to tartrazine or related compounds
  • Current or history of skin conditions such as eczema, psoriasis, or severe inflammatory diseases, defined as scoring ≥16 on the Eczema Area and Severity Index (EASI) or ≥10 on the Psoriasis Area Severity Index (PASI)
  • Other atopic conditions such as asthma, allergic rhinitis, or hypersensitivity reactions
  • Pregnancy or breastfeeding
  • Use of immunosuppressive medications
  • Any condition that may interfere with the safety or results of the study

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Johns Hopkins Hospital

    Baltimore, Maryland, 21287

Other trials in United States

About this study

Official title: Topical Application of Tartrazine for Enhanced Visualization of Subcutaneous Structures in Dermatology

The goal of this clinical trial is to learn if the topical application of tartrazine, an FDA-approved food dye, can help improve the transparency of the skin in healthy volunteers. The main questions it aims to answer are:

  • Can topical tartrazine application allow for temporary skin transparency?
  • What dose of tartrazine is required to achieve reversible skin transparency?

Participants will:

  • Be given a patch test with four different doses of tartrazine
  • Have these patch tests placed on the back, stomach, and forearm
  • Have photographs taken every 5 minutes to see if transparency is achieved
  • Be called 48 hours later to check for any side effects
Read the detailed description

Optical imaging of biological tissues is limited by unwanted scattering and absorption of light, which restricts both the depth of imaging and the spatial resolution. This scattering occurs due to refractive index (RI) mismatches between different tissue components, such as the low RI of water-rich cytosol and the high RI of lipid-based structures. Current methods to reduce light scattering, such as the use of optical clearing agents (OCAs), often involve toxic chemicals or removal of tissue components, making them unsuitable for live imaging.

A recently published study in Science demonstrated that tartrazine, a commonly utilized food dye, is a potent OCA that achieves temporary optical transparency in living tissues. In rodent models, tartrazine was topically administered in a 0.6 M solution and showed reversible transparency effects and rendered their skin, muscle and connective tissues transparent while also providing high-resolution imaging down to the micrometer level without causing tissue damage. Imaging techniques such as laser speckle contrast imaging revealed clear visualization of cerebral blood vessels and internal organs, without needing to surgically remove tissue. Topical application in rodents caused minimal inflammation as affirmed by histological analysis. Additionally, the dye was rapidly cleared via urine and feces without signs of systemic toxicity, and after application, the dye can be washed out to further reduce exposure.

Compared to additional OCAs, tartrazine diffused through tissues more rapidly and required lower concentrations to achieve the desired transparency, resulting in faster visualization. Unlike conventional agents, tartrazine did not cause side effects such as tissue shrinkage or dehydration, making it a promising alternative for non-invasive imaging. These studies established that tartrazine, a strongly absorbing molecule, can reduce the RI mismatch between water and lipids, effectively minimizing light scattering and improving optical transparency.

Tartrazine, also known as FD\&C Yellow No. 5, is a commonly utilized coloring agent found in food products, cosmetics, and medications with approved safety profiles across multiple regulatory bodies, including the US Food and Drug Administration (FDA), Joint Food and Agriculture Organization (FAO) and World Health Organization (WHO) Expert Committee on Food Additives (JECFA), and European Food Safety Authority (EFSA). Although tartrazine has been widely used in food and cosmetics, its clinical use for enhancing reversible skin transparency remains under-explored. The long-standing safety profile of tartrazine, in conjunction with the promising preclinical imaging modulation effects, justifies investigating its efficacy in humans.

Existing optical imaging techniques are limited by penetration depth and high scattering, particularly in vivo. This study aims to fill this gap by using tartrazine to improve visualization in human subjects. The potential benefits of this non-invasive technique for human applications are vast, particularly in dermatology, tumor imaging, and surgical planning. If successful, tartrazine could enable clearer, non-invasive imaging of tumors, vascular lesions, and other subcutaneous structures - providing real-time insights into disease progression and aiding in more accurate medical interventions. This clinical pilot study, with a primary focus on the feasibility of topical tartrazine for improving skin transparency, is built upon the promising results from rodent models and tartrazine's well-established safety profile in humans.

Being tested
Four-Chamber Tartrazine Patch across 3 Body Sites
Keywords
Tartrazine, optical transparency, dermoscopy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Four-Chamber Tartrazine Patch across 3 Body SitesDrug

    Also called FD&C Yellow 5, E102

    This is a chamber patch comprising four increasing doses of tartrazine (0.15M, 0.3M, 0.6M, 1.2M). This will be applied on the forearm, abdomen, and back to represent different skin thicknesses.

Study groups in NCT06800183
Study groupRoleWhat they receive
Tartrazine Patch with 4 Doses across 3 Body SitesExperimentalA four-chamber patch will be loaded with 0.5militer (mL) of tartrazine and applied to 1 cm diameter areas on the skin. Each chamber will deliver one of four different concentrations of a tartrazine solution-0.15 molar concentration (M), 0.3M, 0.6M, and 1.2M-on three distinct skin regions: the anterior forearm (representing thin skin), the abdomen (representing medium-thickness skin), and the back (representing thicker skin). This method ensures consistent, standardized, and simultaneous applications across all skin types and participants, reducing variability in the application process.
Receives: Drug: Four-Chamber Tartrazine Patch across 3 Body Sites

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Optical Transparency as Assessed by Total Transmittance Percentage

    To determine the optimal duration for maximum transparency, serial imaging will be conducted over the course of one 90 minute clinic visit (baseline, immediately post-application, and at 5-minute intervals until transparency plateaus). Imaging will be performed using non-invasive modalities. High-resolution dermoscopy will capture clear images of skin structures, and standardized high-quality photography will document the visible effects of transparency. These images will assess improvements in the resolution, depth, and overall image quality of subdermal structures, allowing the investigators to evaluate whether tartrazine significantly enhances visualization.

    Measured: Up to 90 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jan 2025
  2. Study start11 May 2026 (estimated)
  3. Primary completionDec 2026 (estimated)
  4. Study completionDec 2026 (estimated)

Why it stopped: The investigators are revisiting in vitro and in vivo studies to ensure the ability to replicate the results of the original paper before proceeding to the pilot clinical study.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06800183
Sponsor's protocol ID
IRB00469443
Status last verified
Nov 2025
First submitted
23 Jan 2025
Last updated
14 Nov 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Ntziachristos V. Going deeper than microscopy: the optical imaging frontier in biology. Nat Methods. 2010 Aug;7(8):603-14. doi: 10.1038/nmeth.1483. Epub 2010 Jul 30.

    PubMed 20676081
  • Ou Z, Duh YS, Rommelfanger NJ, Keck CHC, Jiang S, Brinson K Jr, Zhao S, Schmidt EL, Wu X, Yang F, Cai B, Cui H, Qi W, Wu S, Tantry A, Roth R, Ding J, Chen X, Kaltschmidt JA, Brongersma ML, Hong G. Achieving optical transparency in live animals with absorbing molecules. Science. 2024 Sep 6;385(6713):eadm6869. doi: 10.1126/science.adm6869. Epub 2024 Sep 6.

    PubMed 39236186

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing Four-Chamber Tartrazine Patch across 3 Body Sites in people with Healthy and Dermoscopy, run by Johns Hopkins University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 14 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Optical Transparency as Assessed by Total Transmittance Percentage (time frame: Up to 90 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06800183, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in